Ocular Therapeutix, Inc. (OCUL)
OCULNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$6.68
-0.1750 (-2.55%) today
Regular session, Nov 10, 3:24 PM ET
- Market cap
- $1.47bn
- P/E
- –
- EPS, last 4 quarters
- $-1.47
- Dividend yield
- –
- Day range
- $6.60 to $6.87
- 52-week range
- $6.00 to $16.44
- Average volume
- 3.07m
- Previous close
- $6.85
Analysts
7 coveringBuy7 buy, 0 hold, 0 sell
Targets a year out average $25.14, +276.6% from here
Earnings
next estimate $-0.3700Next report
Dec 2025
+12.1%
Mar 2026
-28.1%
Jun 2026
+12.5%
Sep 2026
-16.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $13.25m | $10.79m | $13.47m | $12.87m |
| Gross profit | $11.66m | $9.46m | $11.46m | $11.42m |
| Operating income | -$69.76m | -$93.34m | -$82.11m | -$97.86m |
| Net income | -$64.65m | -$88.61m | -$78.76m | -$94.78m |
Last four quarters: revenue $50.38m, margin -648.6%, free cash flow -$267.04m
News
8 latest- Ocular Tx (OCUL) Q3 2026 Earnings Call TranscriptThe Motley Fool · 1 day ago
- What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings CallMarketBeat · 1 day ago
- Ocular Therapeutix, Inc. Appoints Riad Sherif, M.D. to Board of DirectorsFintel · 1 day ago
- Ocular Therapeutix, Inc. Reports Third Quarter 2026 Financial Results and Cash Balance of $530.6 millionFintel · 1 day ago
- Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue EstimatesZacks · 1 day ago
- NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Beats Revenue EstimatesZacks · 6 days ago
- Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass EstimatesZacks · 7 days ago
- Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 WinMarketBeat · Oct 20, 2026
The company
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI (also known as OTX-TKI), Ocular's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- ocutx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.